Characterization of vaccinia virus growth factor biosynthetic pathway with an antipeptide antiserum.
A synthetic peptide derived from vaccinia virus growth factor (VGF) was used as an immunogen to prepare antiserum able to immunoprecipitate native VGF from both vaccinia virus-infected cell lysate and cell-free medium. Pulse-chase, tunicamycin treatment, and carbohydrate trimming experiments revealed that VGF is synthesized as a 19-kilodalton (kDa) precursor which is rapidly modified to a high-mannose-type 22-kDa protein. This cell-associated form is further processed into a 25-kDa polypeptide which, after proteolytic cleavage, releases the mature VGF into the medium as a 22-kDa glycoprotein.
Chang
W
W
Department of Microbiology and Immunology, University of Washington, Seattle 98195.
Lim
J G
JG
Hellström
I
I
Gentry
L E
LE
D000595:Amino Acid Sequence; D006023:Glycoproteins / Q000096:biosynthesis; D007106:Immune Sera; D036341:Intercellular Signaling Peptides and Proteins; D008969:Molecular Sequence Data; D010452:Peptide Biosynthesis; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology; D010455:Peptides / Q000276:immunology; D011498:Protein Precursors / Q000096:biosynthesis; D011499:Protein Processing, Post-Translational; D014616:Vaccinia virus / Q000276:immunology / Q000378:metabolism*; D014764:Viral Proteins / Q000096:biosynthesis
D006023:Glycoproteins; D007106:Immune Sera; D036341:Intercellular Signaling Peptides and Proteins; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014764:Viral Proteins; C051087:vaccinia growth factor